JP6130495B2 - カンナビノイド受容体活性関連障害及び疾患を調節する方法 - Google Patents

カンナビノイド受容体活性関連障害及び疾患を調節する方法 Download PDF

Info

Publication number
JP6130495B2
JP6130495B2 JP2015514191A JP2015514191A JP6130495B2 JP 6130495 B2 JP6130495 B2 JP 6130495B2 JP 2015514191 A JP2015514191 A JP 2015514191A JP 2015514191 A JP2015514191 A JP 2015514191A JP 6130495 B2 JP6130495 B2 JP 6130495B2
Authority
JP
Japan
Prior art keywords
mnf
cells
receptor
tumor
gpr55
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519347A (ja
JP2015519347A5 (enExample
Inventor
ウェイナー、アーヴィング、ダブリュー．
ベルニエ、ミシェル
ポール、ラジブ、ケイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2015519347A publication Critical patent/JP2015519347A/ja
Publication of JP2015519347A5 publication Critical patent/JP2015519347A5/ja
Application granted granted Critical
Publication of JP6130495B2 publication Critical patent/JP6130495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015514191A 2012-05-25 2013-05-23 カンナビノイド受容体活性関連障害及び疾患を調節する方法 Active JP6130495B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651961P 2012-05-25 2012-05-25
US61/651,961 2012-05-25
US201361789629P 2013-03-15 2013-03-15
US61/789,629 2013-03-15
PCT/US2013/042457 WO2013177418A1 (en) 2012-05-25 2013-05-23 Methods of regulating cannabinoid receptor activity-related disorders and diseases

Publications (3)

Publication Number Publication Date
JP2015519347A JP2015519347A (ja) 2015-07-09
JP2015519347A5 JP2015519347A5 (enExample) 2016-09-29
JP6130495B2 true JP6130495B2 (ja) 2017-05-17

Family

ID=48577922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514191A Active JP6130495B2 (ja) 2012-05-25 2013-05-23 カンナビノイド受容体活性関連障害及び疾患を調節する方法

Country Status (6)

Country Link
US (5) US20150157580A1 (enExample)
EP (1) EP2854855B1 (enExample)
JP (1) JP6130495B2 (enExample)
AU (1) AU2013266235B2 (enExample)
CA (1) CA2874655C (enExample)
WO (1) WO2013177418A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11487195B2 (en) 2018-04-26 2022-11-01 Wonder Vision Techno Laboratory Co., Ltd. Dome screen, dome screen projection apparatus, and method for fabricating the same

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944726A1 (en) * 2014-04-03 2015-10-08 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
US20180042867A1 (en) * 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
BR112018006633A2 (en) * 2015-09-30 2018-10-23 Bird Rock Bio, Inc. antibodies that bind to human cannabinoid receptor 1 (cb1)
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
EP3684797A4 (en) 2017-09-19 2021-07-07 Cannametrix, LLC CELL BASED ASSAY FOR QUANTIFYING THE POWER AND EFFECTIVENESS OF CANNABINOIDS AND / OR TERPENOIDS, AND RELATED METHODS OF USE
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
JP7532754B2 (ja) * 2019-09-04 2024-08-14 株式会社ニコン 画像解析装置、細胞培養観察装置、画像解析方法、及びプログラム
GB202302225D0 (en) * 2023-02-16 2023-04-05 Atrogi Ab New medical uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0639186T3 (da) 1992-04-17 1999-12-13 Abbott Lab Taxolderivater
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
EP1595146B1 (en) * 2003-02-18 2008-04-23 AstraZeneca AB Screening assays for cannabinoid-ligand-type modulators of gpr55
KR101378067B1 (ko) 2006-08-10 2014-04-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 （ｒ,ｒ）―페노테롤 및 （ｒ,ｒ）―또는 （ｒ,ｓ）―페노테롤 유사체의 제조방법 및 이의 울혈성 심부전증 치료를 위한 용도
EP2515946B1 (en) * 2009-12-23 2019-05-22 The Board of Trustees of the University of Illionis Nanoconjugates and nanoconjugate formulations
EP2544676B1 (en) * 2010-03-10 2018-09-19 The United States of America, as represented by The Secretary, Department of Health and Human Services The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11487195B2 (en) 2018-04-26 2022-11-01 Wonder Vision Techno Laboratory Co., Ltd. Dome screen, dome screen projection apparatus, and method for fabricating the same

Also Published As

Publication number Publication date
US20210038540A1 (en) 2021-02-11
AU2013266235A1 (en) 2014-12-04
WO2013177418A1 (en) 2013-11-28
CA2874655C (en) 2020-11-03
JP2015519347A (ja) 2015-07-09
US10485771B2 (en) 2019-11-26
US20160331702A1 (en) 2016-11-17
US20190000781A1 (en) 2019-01-03
US20150157580A1 (en) 2015-06-11
US20200030261A1 (en) 2020-01-30
US10772849B2 (en) 2020-09-15
EP2854855A1 (en) 2015-04-08
AU2013266235B2 (en) 2017-06-08
US11389415B2 (en) 2022-07-19
US10130593B2 (en) 2018-11-20
EP2854855B1 (en) 2016-04-27
CA2874655A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
JP6130495B2 (ja) カンナビノイド受容体活性関連障害及び疾患を調節する方法
US10925840B2 (en) Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2014076453A1 (en) Adrenergic agonists for use in treating liver damage
US20180042867A1 (en) Methods of treating cancer
US20190076379A1 (en) Methods of treating breast cancer
US20180271808A1 (en) Methods of reducing chemoresistance and treating cancer
CA3190860A1 (en) Composition for treating kca3.1 channel-mediated diseases comprising phenylalkyl carbamate compound
US20170172944A1 (en) Methods of treating melanoma
WO2018140923A1 (en) Methods of treating cancer
WO2023183843A1 (en) Combination therapy for treating castration-resistant prostate cancer
US10179142B2 (en) Treatment and/or prevention of bone metastasis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170413

R150 Certificate of patent or registration of utility model

Ref document number: 6130495

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250